Xi Chen

机构：Huzhou Normal University · ORCID：0009-0000-6053-3851

发表论文 149 篇 · 总被引 2514 次 · h-index 24

代表论文

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 661)
• Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies (2024 · Cancer Letters · 被引 19)
• Wnt3a‐Loaded Hydroxyapatite Nanowire@Mesoporous Silica Core−Shell Nanocomposite Promotes the Regeneration of Dentin−Pulp Complex via Angiogenesis, Oxidative Stress Resistance, and Odontogenic Induction of Stem Cells (2023 · Advanced Healthcare Materials · 被引 19)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Association of high-risk comorbidity with overall survival among patients with gastric cancer and its sex-specific differences in China: a retrospective observational cohort study (2023 · BMC Cancer · 被引 11)
• First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study (2025 · Advances in Therapy · 被引 9)